Compound hub · Retatrutide
NCT05882045: what is the TRIUMPH-3 retatrutide trial?
01What it isContents
Somewhere there is a card with your height on it. A blood-pressure reading from a clinic visit, a weight a nurse typed while you sat there, a note filed away and never read again. Your body leaves a written trail wherever it is measured, and you rarely see any of it. A clinical trial is that same habit kept in public: one record, one identifying number, thousands of people written down together. The retatrutide hub keeps this page because retatrutide's trail runs through exactly such a record.
This page reads that record end to end: TRIUMPH-3, a large Phase 3 trial of retatrutide in adults living with both obesity and cardiovascular disease. What follows is what the registry entry says, and what its status field actually means. It covers who was enrolled and what was measured. It covers, just as plainly, what the record has not published. A record can be complete and still tell you nothing about what was found, and knowing that difference is most of what this page is for.
Key facts
| Common name | retatrutide |
|---|---|
| Research code | LY3437943 |
| Registry ID | NCT05882045 |
| Trial acronym | TRIUMPH-3 |
| Registry title | A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease |
| Sponsor | Eli Lilly and Company |
| Other study IDs | 18582 · J1I-MC-GZBM · EU 2023-503659-88-00 |
| Phase | Phase 3 |
| Design | Randomised, double-blind, parallel assignment, interventional |
| Registry status | COMPLETED (status verified July 2026) |
| Enrolment (registry, actual) | 1946 |
| Planned enrolment (design paper) | 1950 |
| Groups | Two retatrutide groups and one placebo group |
| Randomisation ratio (design paper) | 1:1:2 |
| Primary outcome | Percent change from baseline in body weight at Week 80 |
| Key inclusion | Body mass index 35.0 kg/m² or higher, plus established cardiovascular disease |
| Study start (actual) | 30 May 2023 |
| Primary completion (actual) | 16 April 2026 |
| Study completion (actual) | 14 May 2026 |
| First posted | 31 May 2023 |
| Last registry update | 30 July 2026 |
| Listed duration | About 113 weeks |
| Results posted | No |
| Data-sharing plan | Individual participant data via vivli.org, six months after primary publication and US or EU approval, whichever is later |
| Trial phase as of 2026 | Phase 3 |
| Approval as of 2026 | Approved in no country |
What is NCT05882045?
NCT05882045 is the ClinicalTrials.gov registry number for TRIUMPH-3, a Phase 3 trial of retatrutide sponsored by Eli Lilly and Company (ClinicalTrials.gov NCT05882045). A registry number is the public identifier every registered trial carries on the US trial registry. The trial enrolled adults with obesity and established cardiovascular disease. Phase 3 is the large late-stage step, run after smaller safety studies. The record describes a randomised, double-blind, parallel-assignment study comparing retatrutide with placebo. Randomised means groups were assigned by chance. Double-blind means neither participants nor study staff knew a person's group. The registry records 1946 participants enrolled (actual), a primary outcome of percent change from baseline in body weight at Week 80, and a status of COMPLETED (ClinicalTrials.gov NCT05882045).
The full registry title reads "A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease." The entry also carries three other study identifiers: 18582, J1I-MC-GZBM, and EU 2023-503659-88-00 (ClinicalTrials.gov NCT05882045). Those are the sponsor's own filing number, the protocol code, and the European Union registry number. Three filing systems, one trial.
The entry was first posted on 31 May 2023. Its most recent update landed on 30 July 2026 (ClinicalTrials.gov NCT05882045). A registry number is built to stay fixed while everything around it moves: status, dates, enrolment. That is what makes the record worth reading directly, rather than through anyone's summary of it.
Evidence limits
What has NCT05882045 not shown?
The record posts no results. The results section of ClinicalTrials.gov NCT05882045 is empty, and no peer-reviewed TRIUMPH-3 primary results paper existed as of 24 August 2026. A status of COMPLETED records that the trial finished its visits, not that its findings are public (ClinicalTrials.gov NCT05882045). The registry also publishes no milligram amount for either retatrutide group, naming them by number instead (ClinicalTrials.gov NCT05882045). And the registry's actual enrolment of 1946 is not the design paper's planned 1950 (ClinicalTrials.gov NCT05882045; Giblin et al., Diabetes Obes Metab, 2026). Two documents, two figures, and the record does not reconcile them.
TRIUMPH-3 measured body weight in people who already have cardiovascular disease. That is not the same thing as a cardiovascular-outcomes trial, which is built to count heart attacks, strokes, and deaths. The outcomes question sits on a separate registry record, NCT06383390, known as TRIUMPH-Outcomes. A weight result, whenever one is published, would still leave that question open.
Finishing the visits does not start any publication clock either. The registry's data-sharing plan releases individual participant data through vivli.org, and two conditions gate it. The release comes six months after the primary publication, and after United States or European Union approval, whichever comes later (ClinicalTrials.gov NCT05882045). As of 24 August 2026, neither condition had been met. A completed trial can stay unpublished for a long while, and this record says so plainly.
What is published about retatrutide in obesity is earlier and smaller. The Phase 2 trial that came before it enrolled 338 adults and followed them for 48 weeks (Jastreboff et al., NEJM, 2023). That trial is context for the Phase 3 programme, not a part of TRIUMPH-3. No figure from it describes the people in this record.
Is the TRIUMPH-3 trial completed?
Yes, by the registry's own status field. ClinicalTrials.gov NCT05882045 — the record for TRIUMPH-3 — carries a status of COMPLETED, verified in July 2026. The actual study start was 30 May 2023. Actual primary completion was 16 April 2026, and actual study completion was 14 May 2026. Two completion dates exist because they mark two different moments in the same trial. Primary completion is when the last participant was measured for the main outcome. Study completion is when the last participant finished the study altogether.
The entry lists a duration of about 113 weeks for the whole study (ClinicalTrials.gov NCT05882045). A registry entry is a living document. The status field moves as the trial moves, and the results section is a separate part of the record. On this entry, that results section has stayed empty — the gap the limits section above sets out in full.
The record's 30 July 2026 update is the most recent revision on file (ClinicalTrials.gov NCT05882045). Watching that last-updated line is how a reader tells a settled record from a stale one. A page that still moves is a page the sponsor is still maintaining.
Who took part in TRIUMPH-3?
TRIUMPH-3 enrolled 1946 adults aged 18 and over (ClinicalTrials.gov NCT05882045). Entry required a body mass index of 35.0 kg/m² or higher, together with established cardiovascular disease. Body mass index is a weight-for-height figure clinics use as a rough screen. Established means already on record. The registry lists four qualifying events: a previous heart attack (myocardial infarction), an ischemic stroke, a hemorrhagic stroke, or symptomatic peripheral arterial disease (ClinicalTrials.gov NCT05882045). An ischemic stroke is caused by a blocked blood supply, and a hemorrhagic stroke by bleeding. Peripheral arterial disease means narrowed arteries away from the heart, usually in the legs. Symptomatic means the narrowing causes noticeable symptoms, not just a finding on a scan.
The design paper adds the programme's shape around that list. The TRIUMPH trials ran across 13 countries, including Australia, and female enrolment was capped at about 70% (Giblin et al., Diabetes Obes Metab, 2026). A body-composition substudy was planned in about 100 participants, using DXA (Giblin et al., Diabetes Obes Metab, 2026). DXA is a scan that separates fat, lean tissue, and bone.
Entry criteria are the clinic's own shortlist, written down, and they decide what any future number can mean. A result from people with severe obesity and established heart or artery disease is a result about exactly those people. It is not a result about anyone who might have volunteered. Reading who was enrolled is the first step in reading anything the trial later reports.
What did TRIUMPH-3 measure?
The primary outcome of TRIUMPH-3 was the percent change from baseline in body weight at Week 80 (ClinicalTrials.gov NCT05882045). A primary outcome is the one result a trial is built to answer, chosen before it starts. A baseline is the measurement taken before anything begins. The design paper adds the sizing behind it. Each retatrutide group was compared with placebo separately, at 90% power or better, using a two-sample t test at a two-sided alpha of 0.025 (Giblin et al., Diabetes Obes Metab, 2026). Power is the chance a trial of that size detects a real difference if one exists. Alpha is the threshold a result must clear to count as statistically significant.
The design paper describes 80 weeks of treatment followed by 4 weeks of safety follow-up (Giblin et al., Diabetes Obes Metab, 2026). That sits inside the roughly 113 weeks the registry lists for the whole study (ClinicalTrials.gov NCT05882045). The same paper splits the 80 weeks into a 16-week escalation period and a 64-week maintenance period (Giblin et al., Diabetes Obes Metab, 2026). That is trial-design structure on paper, not anything a reader could or should follow.
A Week-80 weight endpoint in a population selected for cardiovascular disease answers a weight question about that population, and nothing more. What the trial was not built to count — the outcomes question — is covered in the limits section above.
What were the groups in TRIUMPH-3?
TRIUMPH-3 ran three groups: two retatrutide groups and one placebo group (ClinicalTrials.gov NCT05882045). The registry identifies the two retatrutide groups by number rather than by amount. The milligram labels come from a different document. The programme design paper describes them as the 9-mg and 12-mg groups, randomised against placebo in a 1:1:2 ratio (Giblin et al., Diabetes Obes Metab, 2026). No milligram figure appears anywhere in the registry entry itself. That absence is exactly why every milligram label on this page names its source.
Read the 1:1:2 ratio as shares: one share to each retatrutide group and two shares to placebo, which made the placebo group the largest of the three (Giblin et al., Diabetes Obes Metab, 2026). This page does not turn the ratio into headcounts. Neither document publishes per-group numbers, and computing them would invent a figure no source contains.
Why would two documents label the same groups differently? A registry field records what the sponsor chose to post, while a design paper is written to be read. The two were never obliged to match, and the gap between them is a labelling gap, not a disagreement about the trial.
How does TRIUMPH-3 fit into the TRIUMPH programme?
TRIUMPH-3 is one of four Phase 3 retatrutide trials described together in the programme's design and rationale paper. That paper covers more than 5800 participants in total (Giblin et al., Diabetes Obes Metab, 2026). Its planned enrolments are TRIUMPH-1 (NCT05929066) at 2300, TRIUMPH-2 (NCT05929079) at 1120, TRIUMPH-3 (NCT05882045) at 1950, and TRIUMPH-4 (NCT05931367) at 435 (Giblin et al., Diabetes Obes Metab, 2026). Each of the four is described as randomised, double-blind, and multicentre. Each compares retatrutide with placebo alongside a healthy diet and physical activity (Giblin et al., Diabetes Obes Metab, 2026).
TRIUMPH-1 is the programme's master protocol, in participants without type 2 diabetes who have obesity or overweight. A master protocol is a single umbrella design running several related sub-studies. Its own registry entry records 2335 enrolled (actual) and a status of COMPLETED, verified in August 2026 (ClinicalTrials.gov NCT05929066). That entry lists a start on 10 July 2023, primary completion on 6 April 2026, and full completion on 30 April 2026, with no results posted (ClinicalTrials.gov NCT05929066). Its primary outcomes include percent body-weight change at Week 80, an apnoea–hypopnoea index measure, and a WOMAC measure (ClinicalTrials.gov NCT05929066). The apnoea–hypopnoea index counts breathing interruptions per hour of sleep, and WOMAC is a joint-pain and function questionnaire. The timeline of how long retatrutide has been studied lives with that sibling page, and this page does not repeat it.
The planned figures for TRIUMPH-2 and TRIUMPH-4 are all the design paper offers for those two records. They are planned, not actual (Giblin et al., Diabetes Obes Metab, 2026). The four TRIUMPH trials share one shape. Each measures body weight, or a related condition endpoint, in a defined population. The cardiovascular-outcomes question sits on a different registry record entirely — the distinction the limits section draws.
Does a completed trial say anything about research material?
No. A registry record describes a study of an investigational compound run under a protocol. It is not a statement about any physical material supplied for laboratory use. TRIUMPH-3 has published no findings in any case, so there is nothing there to read across (ClinicalTrials.gov NCT05882045). Research material is not a medicine, not a substitute for one, and not for human or animal use. Nothing in a trial identifier speaks to the identity, purity, or content of any supplied material. Nor does the trial behind that identifier.
Research-use reference material is not the trial product studied under NCT05882045. No registry entry can stand in for lot documentation. What speaks about a specific physical material is its paperwork: a certificate of analysis for that lot. A trial identifier copied from a registry does not. The catalogue entry for retatrutide reference material places that documentation beside availability. The quality and verification hub walks through what such a certificate records, and what it cannot prove.
Comparison
What the ClinicalTrials.gov record for NCT05882045 states, next to what the TRIUMPH programme design paper states for the same trial. Registry values as recorded on the entry last updated 30 July 2026. Milligram figures are trial-group labels from the design paper, not use directions.
| Field | Registry NCT05882045 | Design paper (Giblin et al., Diabetes Obes Metab, 2026) |
|---|---|---|
| Participants | 1946 enrolled (actual) | 1950 planned |
| Retatrutide groups | Two groups, identified by number rather than by amount | A 9-mg group and a 12-mg group, randomised against placebo 1:1:2 |
| Primary outcome | Percent change from baseline in body weight at Week 80 | Percent change in body weight from baseline to Week 80 — the same endpoint |
| Study length | About 113 weeks listed for the whole study | 80 weeks of treatment plus 4 weeks of safety follow-up |
| Findings | No results posted | A design and rationale paper — it reports no results |
FAQ
What is NCT05882045?
NCT05882045 is the registry number on ClinicalTrials.gov for TRIUMPH-3. TRIUMPH-3 is an Eli Lilly and Company Phase 3 trial of retatrutide in adults with obesity and established cardiovascular disease. The entry lists 1946 participants actually enrolled, a primary outcome built on body-weight change at Week 80, and a COMPLETED status (ClinicalTrials.gov NCT05882045).
Are there results for NCT05882045?
No. No results are posted on the trial's registry entry, and no peer-reviewed TRIUMPH-3 primary results paper had appeared as of 24 August 2026 (ClinicalTrials.gov NCT05882045). The COMPLETED status records that visits finished in May 2026. Publication is a separate step that has not yet happened.
How many people were in TRIUMPH-3?
The registry records an actual enrolment of 1946 (ClinicalTrials.gov NCT05882045). The programme's design paper planned for 1950 (Giblin et al., Diabetes Obes Metab, 2026). The two figures come from different documents and are not interchangeable.
What was the primary endpoint of TRIUMPH-3?
The primary endpoint was the percent change in body weight from baseline at Week 80 (ClinicalTrials.gov NCT05882045). The design paper sized each retatrutide group's comparison with placebo at 90% power or better (Giblin et al., Diabetes Obes Metab, 2026).
Part of
RetatrutideRetatrutide (LY3437943) is an experimental Eli Lilly peptide described in the published literature as acting on three receptor systems at once. This hub collects the questions people ask about it and answers each one from the trial record.
Citations
2 sourcesGiblin K et al. Diabetes, Obesity and Metabolism. 2026;28(1):83-93.
doi:10.1111/dom.70209Jastreboff AM et al. New England Journal of Medicine. 2023;389(6):514-526.
doi:10.1056/NEJMoa2301972
Continue
Retatrutide reference material — batch COA includedResearch use only — not for human or animal use.
Read the retatrutide research guideForm Laboratories supplies research-use-only reference material. This article is an educational summary of published third-party literature. It is not medical advice, not a use instruction, and research material is not for human or animal use.